Peter J. Mariani Acquires 11,363 Shares of Cytosorbents Co. (NASDAQ:CTSO) Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani acquired 11,363 shares of the stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $0.89 per share, for a total transaction of $10,113.07. Following the transaction, the chief financial officer now owns 361,363 shares in the company, valued at approximately $321,613.07. This represents a 3.25 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Cytosorbents Stock Up 13.4 %

CTSO opened at $1.01 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents Co. has a twelve month low of $0.70 and a twelve month high of $2.15. The company has a market cap of $55.23 million, a PE ratio of -2.81 and a beta of 0.57. The company has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.02.

Institutional Trading of Cytosorbents

Several large investors have recently made changes to their positions in CTSO. CM Management LLC lifted its stake in Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares in the last quarter. Sargent Investment Group LLC lifted its position in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the 3rd quarter valued at $51,000. Finally, Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CTSO. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com initiated coverage on Cytosorbents in a research report on Thursday. They issued a “hold” rating for the company.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.